MET and sarcoma: Finally, a limited response of Afatinib combined with Crizotinib for acquired low-level MET amplification was also reported in a NSCLC patient harboring two synchronous uncommon EGFR mutations (exon 18 p.G719S and exon 19 p.L747S) and exhibiting sarcoma-like (spindle and/or giant cell) features [56].